卵巢癌患者血清人激肽释放酶10的检测及其临床意义

J4 ›› 2010, Vol. 36 ›› Issue (3): 540-542.

卵巢癌患者血清人激肽释放酶10的检测及其临床意义

王翠翠¹, 张晓霞¹, 王丽娜¹, 许淑芬², 欧健¹, 田海涵¹

（1.吉林大学第一医院妇产科|吉林长春 130021；2.吉林大学第一医院中心实验室|吉林长春 130021；3.内蒙古自治区通辽市红星医院|内蒙古通辽 028000）

收稿日期:2009-10-16 出版日期:2010-05-28 发布日期:2010-05-28
通讯作者: 张晓霞 E-mail:zhangxx626@yahoo.com.cn
作者简介:王翠翠(1985-)|女|山东省临沂市人|在读医学硕士|主要从事卵巢癌诊断研究。
基金资助:
吉林省教育厅基金资助课题(吉教科合字［2005］第132号)

Detection of serum human kallikrein 10 in patients with ovarian cancer and its clinical significance

WANG Cui-Cui¹, ZHANG Xiao-Xia¹, WANG Li-Na¹, HU Chu-Fen², OU Jian¹, TIAN Hai-Han³

1.Department of Obstetrics and Gynecology,First Hospital,Jilin University,Changchun 130021,China;2.Central Labotatory,First Hospital,Jilin University,Changchun 130021,China;3.Hong Xing Hospital,Tongliao,Inner Mongolia Autonomous region,Tongliao 028000,China)

Received:2009-10-16 Online:2010-05-28 Published:2010-05-28

摘要/Abstract

摘要：

目的：检测卵巢癌患者及其对照组血清人激肽释放酶10(hk10)水平，探讨血清hk10在卵巢癌诊断中的临床意义。方法：ELISA 法检测卵巢癌组(n=50)、卵巢良性肿瘤组(n=20)、妇科良性疾病组(CA125增高,n=26)、妇科其他癌症组(n=18)患者及健康对照组(n=36)血清hk10 水平。结果：卵巢癌组hk10 水平为(15.6±9.23) μg.L^-1，阳性率为88.89%；卵巢良性肿瘤组hk10 水平和阳性率分别为(6.60±2.65) μg.L^-1和10.00%；CA125值增高的妇科良性疾病组血清hk10水平和阳性率分别为(6.92±2.97) μg?L-1和15.38%；妇科其他癌症组hk10 水平和阳性率分别为(6.11±2.42) μg.L^-1和11.11%；对照组hk10 水平为(6.00±2.26) μg.L^-1，阳性率为11.11%；卵巢癌组血清hk10水平和阳性率均显著高于其他各组(P<0.01)。Ⅲ/Ⅳ期卵巢癌组血清hk10水平和阳性率分别为(18.29±9.74) μg.L^-1和94.44%，显著高于Ⅰ/Ⅱ期卵巢癌组的(9.87±4.04) μg.L^-1和75.00%(P<0.01)。卵巢癌组术后血清hk10水平为(13.83±1.56) μg.L^-1，低于术前的hk10水平。结论：卵巢癌组血清hk10水平显著增高，特异性优于CA125，其有望成为卵巢癌新的肿瘤标志物。

关键词: 人血清激肽释放酶10；卵巢肿瘤；CA125

Abstract:

To detect the serum human kallikrein 10 (hk10) expression in patients with ovarian cancer and control groups，and investigate the clinical significance of hk10 in the diagnosis of ovarian cancer. Methods Enzyme-linked immunoassay （ELISA）mothod was used to detect the hk10 levels in serum in ovarian cancer group(n=50),benign ovarian tumor group(n=20),benign gynecological disease (higher CA125 values,n=26),other malignant gynecological cancer group(n=18) and healthy controls(n=36). Results The level of serum hk10 in the ovarian cancer group was(15.60±9.23) μg.L^-1 and the positive rate was 88.89%,in benign ovarian tumor group they were(6.60±2.65) μg.L^-1 and 10.00%;in other malignant gynecological cancer group they were(6.11±2.42) μg?L-1 and 11.11%,in healthy control group they were(6.00±2.26) μg.L^-1 and 11.11%，the level of serum hk10 and the positive rate in ovarian cancer group were higher than those in other groups(P<0.01).The level of serum hk10 and the positive rate in stage Ⅲ/Ⅳ ovarian cancer group were(18.29±9.74) μg?L-1 and 94.44%,they were significantly higher than those in stage Ⅰ / Ⅱ ovarian cancer group(9.87 μg?L-1±4.04 μg.L^-1 and 75.00%)(P<0.01).The level of serum hK10 in patients with ovarian cancer after operation was (13.83±1.56) μg.L^-1 which was lower than before operation.Conclusion The serum hk10 level is significantly increased in ovarian cancer group,its specificity was higher than CA125. hk10 is expected to become a new marker in ovarian cancer.

Key words: human kallikrein 10;ovarian neoplasm;CA125

中图分类号:

R737.31

王翠翠, 张晓霞, 王丽娜, 许淑芬, 欧健, 田海涵. 卵巢癌患者血清人激肽释放酶10的检测及其临床意义[J]. J4, 2010, 36(3): 540-542.

WANG Cui-Cui, ZHANG Xiao-Xia, WANG Li-Na, HU Chu-Fen, OU Jian, TIAN Hai-Han. Detection of serum human kallikrein 10 in patients with ovarian cancer and its clinical significance[J]. J4, 2010, 36(3): 540-542.

[1]	汪萍\|吴小华\|单保恩. LPA1介导溶血磷脂酸对卵巢癌细胞系基质金属蛋白酶2和9释放与活化的调控作用[J]. J4, 2012, 38(4): 709-712.
[2]	秦瑞\|刘俊宝\|曹璐\|田秀娟\|冷维春. 卵巢上皮性癌组织中P21蛋白的表达及其临床意义[J]. J4, 2012, 38(1): 98-101.
[3]	潘颖\|方红娟\|钟磊\|李析蒨\|蔡知天\|宋波\|杜博. 微柱凝胶免疫检测方法检测血清CA125对卵巢上皮性恶性肿瘤的诊断价值[J]. J4, 2012, 38(1): 139-141.
[4]	李艳艳\|张松灵\|张晓霞\|周恒\|王医术. 卵巢浆液性囊腺癌组织中骨桥蛋白的表达及其临床意义[J]. J4, 2012, 38(1): 123-126.
[5]	徐红梅, 李春洪, 夏美慧, 孙连坤, 钟加滕, 何津. 卵巢癌组织差异蛋白的筛选及信号通路的研究[J]. J4, 2010, 36(5): 912-917.
[6]	张晓霞, 孙晓琦, 张松灵, 高咏梅, 田海涵. 卵巢浆液性囊腺癌组织中β-连环蛋白的表达及其意义[J]. J4, 2010, 36(3): 536-539.